Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The comp... Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.2 | 0.2 | 0.2 | 0 | 0 | CS |
| 4 | -0.545 | -73.1543624161 | 0.745 | 0.7999 | 0.121 | 992040 | 0.41557679 | CS |
| 12 | -0.449 | -69.1833590139 | 0.649 | 3.39 | 0.121 | 2690756 | 1.3179237 | CS |
| 26 | -0.75 | -78.9473684211 | 0.95 | 3.39 | 0.121 | 1798320 | 1.26387984 | CS |
| 52 | -5.31 | -96.3702359347 | 5.51 | 7.6699 | 0.121 | 1602669 | 2.23788508 | CS |
| 156 | -68.8 | -99.7101449275 | 69 | 89.566 | 0.121 | 813439 | 6.97404746 | CS |
| 260 | -98.8 | -99.797979798 | 99 | 486.8 | 0.121 | 752683 | 59.01695248 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
